ArticlePloS one2026
Construction of a depression risk prediction model for hepatitis B patients based on machine learning strategy.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Beyond classification metrics: a psychometric-aware benchmark for data augmentation in imbalanced student mental health surveys.Frontiers in digital health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatitis B (HBV) is a chronic viral infection that can lead to cirrhosis, liver failure, and liver cancer, and has a profound impact on the patient's mental health. However, current depression screening mainly relies on self-filled scales and clinical experience, lacking objective and efficient prediction tools. This study aims to construct a risk prediction model for depression in hepatitis B patients based on machine learning, and explore the key features that affect the occurrence of depression, so as to optimize mental health management strategies.
methodsThis study used the NHANES database to collect demographic, dietary, physical examination, laboratory test and questionnaire data. The data were standardized and SMOTE oversampling was used to solve the problem of class imbalance. Random Forest (RF) was used for feature screening to identify the top 20 most important predictive features, and five machine learning models (Gradient Boosting, Logistic Regression, AdaBoost, MLPClassifier, LDA) were used for prediction. The model performance was evaluated by AUC (area under the curve), accuracy, recall, precision and F1-score, and ROC curves, calibration curves, and decision curve analysis (DCA) were drawn to evaluate the clinical applicability of the model.
resultsAll five machine learning models performed well in the task of predicting the risk of depression in hepatitis B patients, among which MLPClassifier (multi-layer perceptron) performed best, with an AUC of 0.935, a recall of 0.980, and an F1-score of 0.917, which was better than other models. In addition, feature analysis results showed that liver function damage (serum total bilirubin, alkaline phosphatase), electrolyte imbalance (serum potassium ions), chronic inflammation (red blood cell distribution width, lymphocyte count), and socioeconomic factors (poverty-income ratio, race) were important factors affecting the risk of depression in hepatitis B patients.
conclusionThis study constructed an efficient and objective machine learning model that can be used to predict the risk of depression in patients with hepatitis B, providing a new tool for accurate screening and individualized management. The study revealed the potential mechanisms of physiological, biochemical and socioeconomic factors in the occurrence of depression in patients with hepatitis B, and provided a reference for future mental health intervention strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.